Emerging European Biotechnology Organization Awards Studies to eResearchTechnology Totaling $1.3 Million for Cardiac Safety Moni

Emerging European Biotechnology Organization Awards Studies to
eResearchTechnology Totaling $1.3 Million for Cardiac Safety Monitoring and
Information Distribution Services
Awards Include a Series of Late Phase Studies for Two Key Clinical Development
Programs 


PHILADELPHIA, March 29  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, announced today that it has been awarded studies
totaling more than $1.3 million in cardiac safety monitoring and services from
an emerging European biotechnology organization for two of its key drug
candidates in later phase clinical trials.

The awards cover a series of Phase III studies that target the two compounds and
will be conducted at 163 research sites distributed across five continents.  eRT
will provide comprehensive support and 163 units of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis.  eRT will perform digital collection,
measurement, interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the first solution
in production that was designed explicitly to meet emerging international
regulatory guidance and technical standards.

"We are delighted with these agreements, which illustrate that the trend toward
program level awards for significant later phase studies is continuing to gain
momentum across all segments and geographies of the drug development industry,"
said Scott Grisanti, senior vice president of business development and chief
marketing officer at eRT.  "We look forward to working closely with this sponsor
to ensure effective conduct of cardiac safety services for these two compounds
in the critical stages of the path to commercialization."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  The studies pertaining to these awards may be canceled by the sponsor
at its sole discretion.  As a result, actual results may differ materially from
any financial outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in the company's
Reports on Forms 10-K and 10-Q filed with the Securities and Exchange
Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright